AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint

AbbVie announced that the Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic s...

Empowering Life Sciences with
Advanced AI Solutions.

Book A Demo
HomeKnolsightsContact UsPricing
One Research Court, Suite 450, Rockville, MD 20850
info@pienomial.com
+91 9876543210
© 2025 Pienomial. All rights reserved
AboutTerms of ServicePrivacy Policy
Home/KnloSights/Clinical Trial Updates/AbbVie's VERONA Trial for Higher-Risk Myelodysplastic Syndromes Misses Primary Endpoint